Treatment of pneumococcal pneumonia: What's in an MIC?

Critical Care Medicine

Volumn 32, Issue 3, 2004, Pages 876-878

  Crnich, Christopher J ^a   Proctor, Richard A ^b  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

NCCLS breakpoints; Outcomes; Penicillin resistance; Pneumonia; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLAVULANIC ACID; ERYTHROMYCIN; MEZLOCILLIN; PENICILLIN G; PIPERACILLIN;

ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; EDITORIAL; HUMAN; LOBAR PNEUMONIA; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PENICILLIN RESISTANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTEREMIA; COMMUNITY-ACQUIRED INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; PENICILLINS; PNEUMONIA, PNEUMOCOCCAL; SURVIVAL RATE;

EID: 1542719536     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000114999.81252.B5     Document Type: Editorial

References (23)

1. Lujan M, Gallego M, Fontanals D, et al: Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality. Crit Care Med 2004; 32:625-631
2. Kalin M, Ortqvist A, Almela M, et al: Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000; 182: 840-847
3. Metlay JP, Hofmann J, Cetron MS, et al: Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30:520-528
4. Waterer GW, Somes GW, Wunderink RG: Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837-1842
5. Martinez JA, Horcajada JP, Almela M, et al: Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389-395
6. Yu VL, Chiou CC, Feldman C, et al: An international prospective study of pneumococcal bacteremia: Correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37: 230-237
7. Turett GS, Blum S, Fazal BA, et al: Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999; 29: 321-327
8. Feikin DR, Schuchat A, Kolczak M, et al: Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90: 223-229
9. Pallares R, Linares J, Vadillo M, et al: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474-480
10. Ewig S, Ruiz M, Torres A, et al: Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999; 159:1835-1842
11. Wu TT, Hsueh PR, Lee LN, et al: Pneumonia caused by penicillin- nonsusceptible Streptococcus pneumoniae: Clinical characteristics, prognostic factors, and outcomes. J Formos Med Assoc 2000; 99:18-23
12. Kim BN, Bae LG, Kim MN, et al: Risk factors for penicillin resistance and mortality in Korean adults with Streptococcus pneumoniae bacteremia. Eur J Clin Microbiol Infect Dis 2002; 21:35-42
13. Tuomanen EI, Austrian R, Masure HR: Pathogenesis of pneumococcal infection. N Engl J Med 1995; 332:1280-1284
14. Craig WA: Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10; quiz 11-12
15. Bryan CS, Talwani R, Stinson MS: Penicillin dosing for pneumococcal pneumonia. Chest 1997; 112:1657-1664
16. National Committee for Clinical Laboratory Standards (2000) Performance Standards for Antimicrobial Susceptibility Testing: Tenth Informational Supplement, M100-S10. National Committee for Clinical Laboratory Standards, Wayne, PA, 2000
17. National Committee for Clinical Laboratory Standards (2002) Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement. Document M100-S12. National Committee for Clinical Laboratory Standards, Wayne, PA, 2002
18. Doern GV, Heilmann KP, Huynh HK, et al: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001; 45:1721-1729
19. Andes D, Craig WA: In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: Application to breakpoint determinations. Antimicrob Agents Chemother 1998; 42: 2375-2379
20. Bartlett JG, Dowell SF, Mandell LA, et al: Practice guidelines for the management of community-acquired pneumonia in adults: Infectious Diseases Society of America. Clin Infect Dis 2000; 31:347-382
21. Mandell LA, Marrie TJ, Grossman RF, et al: Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31:383-421
22. British Thoracic Society Standards of Care Committee: BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001; 56:IV1-IV64
23. Niederman MS, Mandell LA, Anzueto A, et al: Guidelines for the management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-1754